Taipei Veterans General Hospital

Department of Pathology and Laboratory Medicine
No.201, Sec. 2, Shipai Rd., Beitou District, Taipei City, Taiwan
11217, R.O.C.
Tel: 02-2875-7449

Sample Information

Patient Name: 林身立
Gender: Male
ID No.: A100456781
History No.: 36579201
Age: 67

Ordering Doctor: DOC3072G吳佳儒
Ordering REQ.: 0AVPVLP
Signing in Date: 2020/09/03

Path No.: S109-99968
MP No.: F20068
Assay: Oncomine Focus Assay
Sample Type: FFPE
Block No.: S109-28076A+B
Percentage of tumor cells: 50%
Note:

Sample Cancer Type: Non-Small Cell Lung Cancer

Table of Contents

	Page
Variants (Exclude variant in Taiwan BioBank with >1% allele frequency)	2
Biomarker Descriptions	2
Relevant Therapy Summary	3
Relevant Therapy Details	4

Report Highlights

1 Relevant Biomarkers
3 Therapies Available
22 Clinical Trials

Relevant Non-Small Cell Lung Cancer Findings

Gene	Finding	Gene	Finding
ALK	Not detected	NTRK1	Not detected
BRAF	Not detected	NTRK2	Not detected
EGFR	Not detected	NTRK3	Not detected
ERBB2	Not detected	RET	***KIF5B-RET fusion***
KRAS	Not detected	ROS1	Not detected
MET	Not detected		

Relevant Biomarkers

Tier	Genomic Alteration	Relevant Therapies (In this cancer type)	Relevant Therapies (In other cancer type)	Clinical Trials
IA	*KIF5B-RET fusion* kinesin family member 5B - ret proto-oncogene	**selpercatinib** [1] cabozantinib	**selpercatinib** [1]	22

Public data sources included in relevant therapies: FDA[1], NCCN, **EMA**[2], ESMO
Tier Reference: Li et al. *Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists.* J Mol Diagn. 2017 Jan;19(1):4-23.

Relevant Biomarkers (continued)

Tier	Genomic Alteration	Relevant Therapies (In this cancer type)	Relevant Therapies (In other cancer type)	Clinical Trials
		vandetanib		

Public data sources included in relevant therapies: FDA[1], NCCN, **EMA**[2], ESMO
Tier Reference: Li et al. *Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists.* J Mol Diagn. 2017 Jan;19(1):4-23.

Prevalent cancer biomarkers without relevant evidence based on included data sources
CTNNB1 p.(S33C) c.98C>G

Variants (Exclude variant in Taiwan BioBank with >1% allele frequency)

DNA Sequence Variants

Gene	Amino Acid Change	Coding	Variant ID	Locus	Allele Frequency	Transcript	Variant Effect	Coverage
CTNNB1	p.(S33C)	c.98C>G	COSM5677	chr3:41266101	27.20%	NM_001904.3	missense	1125
FGFR1	p.(=)	c.2178T>G	.	chr8:38271771	4.92%	NM_001174067.1	synonymous	772
JAK3	p.(E547*)	c.1639G>T	.	chr19:17948803	4.50%	NM_000215.3	nonsense	1999

Gene Fusions (RNA)

Genes	Variant ID	Locus
KIF5B-RET	KIF5B-RET.K15R12.COSF1232	chr10:32317356 - chr10:43612032

Biomarker Descriptions

CTNNB1 (catenin beta 1)

Background: The CTNNB1 gene encodes catenin beta-1 (β-catenin), an integral component of cadherin-based adherens junctions involved in maintaining adhesion and regulating the growth of epithelial cell layers[1]. CTNNB1 binds to the APC protein in the cytoplasm and also interacts with TCF and LEF transcription factors in the nucleus to regulate WNT signaling[2]. Steady state levels of CTNNB1 are regulated by ubiquitin-dependent proteolysis[3,4,5].

Alterations and prevalence: Recurrent somatic mutations leading to CTNNB1 activation are common in cancer. The most prevalent alterations include missense mutations in exon 3 at codons S33, S37, T41, and S45 that block phosphorylation by GSK-β and inhibit CTNNB1 degradation[6,7,8,9]. These activating mutations are observed in diverse solid tumors and have a prevalence of 20-30% in hepatocellular carcinoma, 20% of uterine carcinoma, and 15% of adrenocortical carcinoma[10,11,12,13,14,15,16].

Potential relevance: Currently, no therapies have been approved for CTNNB1 aberrations. CTNNB1 alterations in EGFR positive lung cancer have been proposed to promote cancer progression and limit the response to EGFR tyrosine kinase inhibitors[17].

RET (ret proto-oncogene)

Background: The RET gene encodes the RET receptor tyrosine kinase which is activated by a ligand family of glial cell line-derived neurotrophic factors (GDNF)[18]. RET is the target of recurrent chromosomal rearrangements that generate fusion proteins containing the intact RET tyrosine kinase domain combined with several fusion partner genes. RET fusion kinases are constitutively activated and

Biomarker Descriptions (continued)

drive oncogenic transformation which can lead to activation of PI3K/AKT, RAS/RAF/MEK/ERK, and PLCγ/PKC pathways resulting in cell survival and proliferation[19].

Alterations and prevalence: RET fusions occur in approximately 55% of papillary thyroid carcinomas (PTC) with even higher frequencies observed in PTC patients with radiation exposure[20,21,22]. RET rearrangement is also present in 1-2% of non-small cell lung cancer (NSCLC)[23]. Point mutations in RET are relatively common in sporadic medullary thyroid cancer (MTC), with 6% of patients found to contain germline mutations[24]. Somatic mutations (specifically at codon 918), which leads to increased kinase activity, have been observed in at least 25% of MTC cases[24].

Potential relevance: Selpercatinib[25] is approved (2020) for RET fusion-positive NSCLC and thyroid cancer. Selpercatinib[25] is also approved for RET-mutation positive medullary thyroid cancer (MTC). Additionally, the RET inhibitor, pralsetinib[26], was granted breakthrough therapy designation for RET mutation-positive medullary thyroid cancer (2019) as well as for RET fusion-positive NSCLC (2020). The FDA approved small-molecule tyrosine kinase inhibitors, vandetanib (2011), and cabozantinib (2012), are recommended for the treatment of NSCLC patients with RET rearrangements[27]. Cabozantinib has also demonstrated clinical benefit in RET mutated medullary thyroid cancer patients[28]. Point mutations involving codons 804 and 806 have been shown to confer resistance to selective kinase inhibitors including vandetanib[29,30]. RET mutations at codon 918 are associated with high risk and adverse prognosis in patients diagnosed with MTC[31].

Relevant Therapy Summary

● In this cancer type ○ In other cancer type ◑ In this cancer type and other cancer types ⊘ Contraindicated ⚠ Both for use and contraindicated ✖ No evidence

KIF5B-RET fusion

Relevant Therapy	FDA	NCCN	EMA	ESMO	Clinical Trials*
selpercatinib	◑	●	✖	✖	● (II)
cabozantinib	✖	●	✖	✖	● (II)
vandetanib	✖	●	✖	✖	✖
alectinib	✖	✖	✖	✖	● (IV)
alectinib, crizotinib	✖	✖	✖	✖	● (III)
ipilimumab, nivolumab, radiation therapy, surgical intervention	✖	✖	✖	✖	● (III)
pralsetinib	✖	✖	✖	✖	● (III)
selpercatinib, chemotherapy, pembrolizumab	✖	✖	✖	✖	● (III)
erdafitinib	✖	✖	✖	✖	● (II)
ponatinib	✖	✖	✖	✖	● (II)
sunitinib	✖	✖	✖	✖	● (II)
targeted therapy, chemotherapy	✖	✖	✖	✖	● (II)

* Most advanced phase (IV, III, II/III, II, I/II, I) is shown and multiple clinical trials may be available.

Relevant Therapy Summary (continued)

● In this cancer type ○ In other cancer type ◑ In this cancer type and other cancer types ⊘ Contraindicated ⚠ Both for use and contraindicated ✖ No evidence

KIF5B-RET fusion (continued)

Relevant Therapy	FDA	NCCN	EMA	ESMO	Clinical Trials*
TPX-0046	✖	✖	✖	✖	● (I/II)
BOS172738	✖	✖	✖	✖	● (I)

* Most advanced phase (IV, III, II/III, II, I/II, I) is shown and multiple clinical trials may be available.

Relevant Therapy Details

Current FDA Information

● In this cancer type ○ In other cancer type ◑ In this cancer type and other cancer types ⊘ Contraindicated ⛔ Not recommended 🛡 Resistance

FDA information is current as of 2020-05-26. For the most up-to-date information, search www.fda.gov.

KIF5B-RET fusion

◑ selpercatinib

Cancer type: Non-Small Cell Lung Cancer, Poorly Differentiated Thyroid Gland Carcinoma, Thyroid Gland Anaplastic Carcinoma, Thyroid Gland Hurthle Cell Carcinoma, Thyroid Gland Papillary Carcinoma

Label as of: 2020-05-08

Variant class: RET fusion

Indications and usage:

RETEVMO™ is a kinase inhibitor indicated for the treatment of:

- Adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC)[1]
- Adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy[1]
- Adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate)[1]

[1] This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).

Reference:

https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf

Current NCCN Information

● In this cancer type ○ In other cancer type ◑ In this cancer type and other cancer types ⊘ Contraindicated ⊖ Not recommended ⛊ Resistance

NCCN information is current as of 2020-05-01. For the most up-to-date information, search www.nccn.org.
For NCCN International Adaptations & Translations, search www.nccn.org/global/international_adaptations.aspx.

KIF5B-RET fusion

● cabozantinib

Cancer type: Non-Small Cell Lung Cancer **Variant class:** RET fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):
- Adenocarcinoma, Large Cell, Non-Small Cell Lung Cancer (NOS), Squamous Cell Carcinoma; Advanced or metastatic disease; RET rearrangement discovered prior to or during first-line systemic therapy (First-line therapy) (Useful in Certain Circumstances)
- Non-Small Cell Lung Cancer; Advanced or metastatic disease; Progression after first-line systemic therapy (Subsequent therapy) (Useful in Certain Circumstances)

Reference: NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 4.2020]

● selpercatinib

Cancer type: Non-Small Cell Lung Cancer **Variant class:** RET fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):
- Adenocarcinoma, Large Cell, Non-Small Cell Lung Cancer (NOS), Squamous Cell Carcinoma; RET rearrangement discovered prior to or during first-line systemic therapy (First-line therapy) (Preferred)
- Non-Small Cell Lung Cancer; Advanced or metastatic disease; Subsequent therapy if not previously used in first-line (Subsequent therapy) (Preferred)

Reference: NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 4.2020]

● vandetanib

Cancer type: Non-Small Cell Lung Cancer **Variant class:** RET fusion

NCCN Recommendation category: 2B

Population segment (Line of therapy):
- Adenocarcinoma, Large Cell, Non-Small Cell Lung Cancer (NOS), Squamous Cell Carcinoma; RET rearrangement discovered prior to or during first-line systemic therapy (First-line therapy) (Useful in Certain Circumstances)
- Non-Small Cell Lung Cancer; Advanced or metastatic disease; If not previously used in first-line (Subsequent therapy) (Useful in Certain Circumstances)

Reference: NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 4.2020]

KIF5B-RET fusion (continued)

atezolizumab

Cancer type: Non-Small Cell Lung Cancer **Variant class:** RET fusion

Summary:
NCCN Guidelines® include the following supporting statement(s):
- "Patients with RET rearrangements have minimal response (6%) to immunotherapy."

Reference: NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 4.2020]

durvalumab

Cancer type: Non-Small Cell Lung Cancer **Variant class:** RET fusion

Summary:
NCCN Guidelines® include the following supporting statement(s):
- "Patients with RET rearrangements have minimal response (6%) to immunotherapy."

Reference: NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 4.2020]

nivolumab

Cancer type: Non-Small Cell Lung Cancer **Variant class:** RET fusion

Summary:
NCCN Guidelines® include the following supporting statement(s):
- "Patients with RET rearrangements have minimal response (6%) to immunotherapy."

Reference: NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 4.2020]

pembrolizumab

Cancer type: Non-Small Cell Lung Cancer **Variant class:** RET fusion

Summary:
NCCN Guidelines® include the following supporting statement(s):
- "Patients with RET rearrangements have minimal response (6%) to immunotherapy."

Reference: NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 4.2020]

Signatures

Testing Personnel:

Shu-Ying Wang 2020.09.03 15:09:58 +08'00'

Laboratory Supervisor:

2020.09.03 15:10:14 +08'00'

Pathologist:

2020.09.03
15:10:33 +08'00'

References

1. Valenta et al. The many faces and functions of β-catenin. EMBO J. 2012 Jun 13;31(12):2714-36. PMID: 22617422
2. Korinek et al. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science. 1997 Mar 21;275(5307):1784-7. PMID: 9065401
3. Aberle et al. beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J. 1997 Jul 1;16(13):3797-804. PMID: 9233789
4. Winston et al. The SCFbeta-TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IkappaBalpha and beta-catenin and stimulates IkappaBalpha ubiquitination in vitro. Genes Dev. 1999 Feb 1;13(3):270-83. PMID: 9990852
5. Kitagawa et al. An F-box protein, FWD1, mediates ubiquitin-dependent proteolysis of beta-catenin. EMBO J. 1999 May 4;18(9):2401-10. PMID: 10228155
6. Liu et al. Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell. 2002 Mar 22;108(6):837-47. PMID: 11955436
7. Miyoshi et al. Activation of the beta-catenin gene in primary hepatocellular carcinomas by somatic alterations involving exon 3. Cancer Res. 1998 Jun 15;58(12):2524-7. PMID: 9635572
8. Gao et al. Exon 3 mutations of CTNNB1 drive tumorigenesis: a review. Oncotarget. 2018 Jan 12;9(4):5492-5508. PMID: 29435196
9. Morin et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science. 1997 Mar 21;275(5307):1787-90. PMID: 9065402
10. Schulze et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat. Genet. 2015 May;47(5):505-511. PMID: 25822088
11. Ahn et al. Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification. Hepatology. 2014 Dec;60(6):1972-82. PMID: 24798001
12. Harding et al. Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies. Clin. Cancer Res. 2018 Oct 29. PMID: 30373752
13. Cancer et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013 May 2;497(7447):67-73. PMID: 23636398
14. Soumerai et al. Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer. Clin. Cancer Res. 2018 Dec 1;24(23):5939-5947. PMID: 30068706
15. Weinstein et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat. Genet. 2013 Oct;45(10):1113-20. PMID: 24071849
16. Cerami et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012 May;2(5):401-4. PMID: 22588877
17. Blakely et al. Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. Nat. Genet. 2017 Dec;49(12):1693-1704. PMID: 29106415
18. Knowles et al. Structure and chemical inhibition of the RET tyrosine kinase domain. J. Biol. Chem. 2006 Nov 3;281(44):33577-87. PMID: 16928683
19. Ibáñez. Structure and physiology of the RET receptor tyrosine kinase. Cold Spring Harb Perspect Biol. 2013 Feb 1;5(2). PMID: 23378586
20. Santoro et al. Central role of RET in thyroid cancer. Cold Spring Harb Perspect Biol. 2013 Dec 1;5(12):a009233. PMID: 24296167
21. Elisei et al. RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults. J. Clin. Endocrinol. Metab. 2001 Jul;86(7):3211-6. PMID: 11443191
22. Ciampi et al. RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis. Endocrinology. 2007 Mar;148(3):936-41. PMID: 16946010
23. Kohno et al. KIF5B-RET fusions in lung adenocarcinoma. Nat. Med. 2012 Feb 12;18(3):375-7. PMID: 22327624
24. Wohllk et al. Relevance of RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. J. Clin. Endocrinol. Metab. 1996 Oct;81(10):3740-5. PMID: 8855832
25. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf

References (continued)

26. http://ir.blueprintmedicines.com/news-releases/news-release-details/blueprint-medicines-reports-first-quarter-2019-financial-results
27. NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 4.2020]
28. Sherman et al. Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer. Cancer. 2016 Dec 15;122(24):3856-3864. PMID: 27525386
29. Carlomagno et al. Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors. Oncogene. 2004 Aug 12;23(36):6056-63. PMID: 15184865
30. Carlomagno et al. Identification of tyrosine 806 as a molecular determinant of RET kinase sensitivity to ZD6474. Endocr Relat Cancer. 2009 Mar;16(1):233-41. doi: 10.1677/ERC-08-0213. Epub 2008 Nov 24. PMID: 19029224
31. NCCN Guidelines® - NCCN-Thyroid Carcinoma [Version 2.2019]